Life Sciences on the Rise: 2021 North American Report

Public & Private Investment, 2010 through Now

THE TOP 10 MARKETS CAPTURED 43% OF TOTAL FUNDING OVER THE LAST FIVE YEARS: (Total Funding 2016-2021)

A record $37 billion of private equity and $33 billion of public investment poured into North American life sciences companies in 2020. The combined total, a 93% increase from the previous record investment received in 2018, could be topped in 2021. The deal timeframe for these investments being long, it is clear that 2020 would likely have been a record year of investment for life sciences companies without the global COVID-19 outbreak, though many observers expect there to be potentially increased focus on biotechnology solutions as a long-term impact from the pandemic. NORTH AMERICAN BIOTECHNOLOGY VENTURE AND PUBLIC OFFERING CAPITAL RAISES 2020 THROUGH APRIL 2021

BOSTON

$12.9B

NEW YORK CITY

$10.6B

SAN FRANCISCO BAY AREA

$8.1B

SEATTLE

$60.0

$5.7B

$57.3

LOS ANGELES

$50.0

$5.3B

PE Public

PHILADELPHIA

$40.0

$5.3B

$37.4

BALTIMORE

$30.0

$32.9

$32.8

$5.0B

$ Invested in Billions

SAN DIEGO

$20.0

$24.7

$4.9B

$22.5

$17.3

CHICAGO

$10.0

$13.9

$13.3

$4.0B

$12.4

$11.6

$11.3

$9.9

$9.8

$9.5

$8.9

$7.6

$7.1

$2.7

RALEIGH/DURHAM

$6.5

$2.3

$6.4

$6.2

$5.9

$0.0

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021P

$3.5B

Note: 2021 estimates based on Q1-2021 actual data at an annual rate.

Source: U.S. National Institutes of Health

Source: PitchBook

/ 7